Semaglutide is a GLP-1 receptor agonist while tirzepatide activates both GIP and GLP-1 receptors, which can lead to larger average weight loss in some trials
The Wegovy pill showed roughly similar weight loss and side effects in clinical trials as the Wegovy shot, and will be available by prescription in the US in January, according to Novo Nordisk
PYY 3-36 crosses the bloodbrain-barrier 26 and inhibits food intake via its interactions with Y2-R in brain areas that regulate energy homeostasis, including the ARC of the hypothalamus and the AP and NTS of the hindbrain 27,28,29,30
This could involve making medication adjustments, such as changing your dose or considering if a different medication might be more effective for you
In the context of AD, the focus should be on individuals at risk, such as those with MCI, subjective cognitive decline, elders with positive A or tau biomarkers, APOE -4-carriers or healthy elderly individuals with high-risk scores [105]